Literature DB >> 947582

Echocardiographic assessment of the level of cardiac compensation in valvular heart disease.

A Rosenblatt, R Clark, J Burgess, K Cohn.   

Abstract

The level of cardiac compensation in valvular disease was studied by relating echocardiographic and cardiac catheterization measurements. Three groups -- compensated, intermediately compensated, and decompensated -- were defined according to the left ventricular angiographic pattern and cardiac output. The echocardiographic ejection indices, percent left ventricular minor diameter shortening, ejection fraction, and fiber shortening rate were significantly higher than normal in compensated mitral regurgitation, lower then normal in compensated aortic stenosis, and within normal limits in compensated aortic insufficiency. In the decomposed state these indices were depressed. Intermediate compensation was best recognized by combining several echocardiographic variables into an echocardiographic score based on multivariate discriminant function analysis. Thus, the compensated volume overload states (aortic and mitral regurgitation) and pressure overload state (aortic stenosis) have separate sets of "normal" echocardiographic values; low ejection indices characterize the decompensated group, while recognition of intermediate compensation requires analysis of multiple echocardiographic variables.

Entities:  

Mesh:

Year:  1976        PMID: 947582     DOI: 10.1161/01.cir.54.3.509

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  2 in total

1.  Non-rheumatic mitral regurgitation.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-27

2.  Pathophysiological background and prognostic implication of systolic aortic root motion in non-ischemic dilated cardiomyopathy.

Authors:  Matthias Aurich; Matthias Niemers; Patrick Fuchs; Sebastian Greiner; Matthias Müller-Hennessen; Lorenz Uhlmann; Evangelos Giannitsis; Philipp Ehlermann; Benjamin Meder; Hugo A Katus; Derliz Mereles
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.